Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics

Abstract Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.1%) is...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura M. Periman, Darrell E. White, Douglas Katsev
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-01-01
Series:Ophthalmology and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s40123-024-01076-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585960396685312
author Laura M. Periman
Darrell E. White
Douglas Katsev
author_facet Laura M. Periman
Darrell E. White
Douglas Katsev
author_sort Laura M. Periman
collection DOAJ
description Abstract Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.1%) is formulated to increase ocular delivery of its active ingredient to improve tear production. The two medications utilize the distinctive properties of two different semifluorinated alkanes (SFAs) to elicit their therapeutic effects. PFHO consists of 100% active ingredient and forms a monolayer on the surface of the tear film to inhibit evaporation. CsA 0.1% utilizes a vehicle consisting of perfluorobutylpentane (PFBP) and ethanol to facilitate delivery of cyclosporine to ocular tissues. The structure of these SFAs determines their differing behaviors and functions. The longer chain length of PFHO results in a slower evaporation rate and facilitates formation of a stable monolayer on the ocular surface. In vitro, PFHO demonstrated a substantially lower evaporation rate versus PFBP or human meibum, as well as a significantly longer ocular surface residence time. Ex vivo, PFHO demonstrated a longer ocular surface residence time than PFBP. The shorter chain length of PFBP enables it to better solubilize cyclosporine and improve drug delivery to ocular tissues. Although both of these ophthalmic drops utilize SFAs, their differences—in physicochemical properties and the mechanisms by which they are understood to intervene in the DED cycle—are important considerations in treatment selection for patients with DED.
format Article
id doaj-art-003b23f6d34c44d8bcc5f52544066407
institution Kabale University
issn 2193-8245
2193-6528
language English
publishDate 2025-01-01
publisher Adis, Springer Healthcare
record_format Article
series Ophthalmology and Therapy
spelling doaj-art-003b23f6d34c44d8bcc5f525440664072025-01-26T12:18:47ZengAdis, Springer HealthcareOphthalmology and Therapy2193-82452193-65282025-01-0114228329310.1007/s40123-024-01076-wDifferentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical CharacteristicsLaura M. Periman0Darrell E. White1Douglas Katsev2Periman Eye InstituteSkyvision CentersSanta Barbara Eye CareAbstract Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.1%) is formulated to increase ocular delivery of its active ingredient to improve tear production. The two medications utilize the distinctive properties of two different semifluorinated alkanes (SFAs) to elicit their therapeutic effects. PFHO consists of 100% active ingredient and forms a monolayer on the surface of the tear film to inhibit evaporation. CsA 0.1% utilizes a vehicle consisting of perfluorobutylpentane (PFBP) and ethanol to facilitate delivery of cyclosporine to ocular tissues. The structure of these SFAs determines their differing behaviors and functions. The longer chain length of PFHO results in a slower evaporation rate and facilitates formation of a stable monolayer on the ocular surface. In vitro, PFHO demonstrated a substantially lower evaporation rate versus PFBP or human meibum, as well as a significantly longer ocular surface residence time. Ex vivo, PFHO demonstrated a longer ocular surface residence time than PFBP. The shorter chain length of PFBP enables it to better solubilize cyclosporine and improve drug delivery to ocular tissues. Although both of these ophthalmic drops utilize SFAs, their differences—in physicochemical properties and the mechanisms by which they are understood to intervene in the DED cycle—are important considerations in treatment selection for patients with DED.https://doi.org/10.1007/s40123-024-01076-wAnti-evaporativeCyclosporineDry eyeImmunomodulatorPerfluorobutylpentanePerfluorohexyloctane
spellingShingle Laura M. Periman
Darrell E. White
Douglas Katsev
Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
Ophthalmology and Therapy
Anti-evaporative
Cyclosporine
Dry eye
Immunomodulator
Perfluorobutylpentane
Perfluorohexyloctane
title Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
title_full Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
title_fullStr Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
title_full_unstemmed Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
title_short Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
title_sort differentiating between perfluorohexyloctane ophthalmic solution and water free cyclosporine ophthalmic solution 0 1 for dry eye disease a review of preclinical and clinical characteristics
topic Anti-evaporative
Cyclosporine
Dry eye
Immunomodulator
Perfluorobutylpentane
Perfluorohexyloctane
url https://doi.org/10.1007/s40123-024-01076-w
work_keys_str_mv AT lauramperiman differentiatingbetweenperfluorohexyloctaneophthalmicsolutionandwaterfreecyclosporineophthalmicsolution01fordryeyediseaseareviewofpreclinicalandclinicalcharacteristics
AT darrellewhite differentiatingbetweenperfluorohexyloctaneophthalmicsolutionandwaterfreecyclosporineophthalmicsolution01fordryeyediseaseareviewofpreclinicalandclinicalcharacteristics
AT douglaskatsev differentiatingbetweenperfluorohexyloctaneophthalmicsolutionandwaterfreecyclosporineophthalmicsolution01fordryeyediseaseareviewofpreclinicalandclinicalcharacteristics